InMode Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
UBS Adjusts Price Target on InMode to $20 From $26, Maintains Neutral Rating
InMode (INMD) has an average outperform rating and a price target range of $20 to $33, according to analysts polled by Capital IQ. Price: 17.52, Change: +0.16, Percent Change: +0.92
Needham: Reiterates that InMode (INMD.US) holds the rating.
Needham: Reiterates that InMode (INMD.US) holds the rating.
Needham Reiterates Hold on InMode
Needham analyst Mike Matson reiterates InMode (NASDAQ:INMD) with a Hold.
InMode Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 — Needham Reiterates → Hold 04/12/2024 86.44% Barclays $34 → $33 Maintains Overweight 04/09/20
Earnings Call Summary | InMode(INMD.US) Q1 2024 Earnings Conference
The following is a summary of the InMode Ltd. (INMD) Q1 2024 Earnings Call Transcript:Financial Performance:InMode reported Q1 2024 revenue of $80.3 million. Pro forma revenue, including pre-orders no
Analysts Conflicted on These Healthcare Names: InMode (INMD) and Pfizer (PFE)
InMode Shares Rise; Q1 Non-GAAP Earnings, Revenue Fall; 2024 Guidance Cut
InMode (INMD) shares rose 2.4% in recent Thursday even after the company reported declines in Q1 profit and revenue and cut 2024 guidance. The medical-products company reported Q1 non-GAAP earnings of
InMode (INMD.US): The 2024 Q1 financial report achieved revenue of US$80.284 million, prior value of US$106.1 million, expected value of US$93.02 million; earnings per share were US$0.32, previous value was US$0.52, and expected value was US$0.44.
InMode (INMD.US): The 2024 Q1 financial report achieved revenue of US$80.284 million, prior value of US$106.1 million, expected value of US$93.02 million; earnings per share were US$0.32, previous value was US$0.52, and expected value was US$0.44.
InMode Announces Q1 Results and Share Buyback
InMode Cuts 2024 View To Rev $485M-$495M >INMD
InMode Cuts 2024 View To Rev $485M-$495M >INMD
InMode Appoints Michael Anghel Chairman of the Board Effective July 25 >INMD
InMode Appoints Michael Anghel Chairman of the Board Effective July 25 >INMD
InMode Announces Shr Repurchase Program of Up to 8.37M Shrs >INMD
InMode Announces Shr Repurchase Program of Up to 8.37M Shrs >INMD
Earnings Flash (INMD) INMODE Posts Q1 EPS $0.32, Vs. Street Est of $0.41
07:04 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (INMD) INMODE Posts Q1 EPS $0.32, vs. Street Est of $0.41
InMode 1Q EPS 28c >INMD
InMode 1Q EPS 28c >INMD
Press Release: InMode Reports First Quarter 2024 Financial Results; Quarterly Revenue of $80.3M Represents 24% Year-Over-Year Decrease; Pro Forma Revenue (Including New Platform Pre-orders Not yet Available) of $96M;
InMode Reports First Quarter 2024 Financial Results; Quarterly Revenue of $80.3M Represents 24% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet available) of $96M
InMode Reports First Quarter 2024 Financial Results; Quarterly Revenue of $80.3M Represents 24% Year-Over-Year Decrease; Pro Forma Revenue (Including New Platform Pre-orders Not yet Available) of $96M;
Company Announces Share Repurchase Program of Up to 8.37 Million Shares; andAppoints New Chairman of the Board of DirectorsYOKNEAM, Israel, May 2, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InM
InMode Reports First Quarter 2024 Financial Results; Quarterly Revenue of $80.3M Represents 24%...
InMode Defends Its Feminine Rejuvenation Patent Against BTL Industries' Review Request
InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, responded to the recent petition to the U.S. Patent & Trademark Office filed by BTL Industries, Inc., in which
InMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTL
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, responded to the recent petition to the U.S. Patent &...
No Data